Scripps Research, Model Medicines Partner to Develop COVID-19 Therapeutics
What You Should Know
Model Medicines has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19.
The partnership will leverage Model Medicines CHEMprint™ AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19.
Scripps Research is teaming up with Model Medicines, an AI drug discovery company to develop COVID-19 therapeutics. The partnership will leverage Model Medicines CHEMprint™ AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19. Previously, the company has successfully utilized the platform to discover REP-001, REP-002, and REP-003 – three Phase II/III ready small molecule assets for the treatment of gastric, neurological, and weight disorders, respectively.
Partnership Details
Scripps Research scientists together with Calibr, its drug development division, will leverage its COVID-19 screening models and commitment to drug repurposing as part of the partnership. Calibr previously established the ReFRAME collection, the world’s leading collection of known drugs, comprising over 14,000 compounds that have been approved by the FDA for other diseases or have been extensively tested for human safety, which it is bringing to bear on the current pandemic. The collaborative work with Model Medicines will augment this effort by characterizing compounds not identified to date using conventional repurposed drug screening approaches.
“We could not be more excited about our partnership with Scripps Research and Calibr. Like Model Medicines, Calibr is committed to ending the scourge of the global COVID-19 pandemic. Our goal is to move therapeutics from the computer to the clinic in a fraction of the time typically required to discover and bring new drugs to market and alleviate the suffering of patients afflicted by COVID-19. Creating therapeutics to treat COVID-19 also allows the global community to go back to work and for children to go back to school. Model Medicines and Calibr are committed to doing our part to ensure that happens sooner rather than later,” said Dr. Daniel Haders II, Ph.D., Executive Chairman at Model Medicines.
AI-DRIVEN DRUG DISCOVERY
Model Medicines, a Nex Cubed digital health portfolio company, has harnessed the predictive prowess of artificial intelligence and machine learning with its CHEMprint™ AI Drug Discovery Platform to discover drugs that may be repurposed to serve as therapeutics to treat patients suffering from COVID-19. The drugs that Model Medicines discovers for COVID-19 can enter clinical trials in as little as several months.
MODEL MEDICINES DRUG LIBRARY
Model Medicines Drug Library is comprised of approximately 4,000 drug compounds that have been approved for commercial use by the U.S. FDA, or similar agencies, and 20,000+ drug compounds that are known to have successfully navigated a Phase I (human safety) clinical trial. All drugs have a full pre-clinical program, an existing or legacy supply chain, and are known to be safe and well-tolerated in humans.
This article originally appeared on HIT Consultant, prior to the rebrand of Repurpose.AI to Model Medicines, read the full article here.
